- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07425743
Conventional Non-Penetrating Deep Sclerectomy Versus Modified Subflap Mattress Suture in OAG
Comparison Between Conventional Non-Penetrating Deep Sclerectomy and Modified Technique With Subflap Mattress Suture in Patients With Open-Angle Glaucoma
The goal of this clinical trial is to learn if modified non-penetrating deep sclerectomy (NPDS) with a sub-flap mattress suture works to treat open-angle glaucoma (OAG). It will also learn about the safety and effectiveness of this modified surgical approach. The main questions it aims to answer are:
Does the modified NPDS technique result in significantly lower and more persistent intraocular pressure (IOP) reduction compared to the conventional technique? What is the rate of complete success (IOP 6-18 mmHg without medication) and qualified success (IOP 6-18 mmHg with medication) for both groups? What postoperative complications or medical problems (such as iris prolapse, conjunctival leaks, or IOP spikes) do participants experience?
Researchers will compare Modified Deep Sclerectomy with Ahmed's sub-flap mattress suture to standard conventional NPDS to see which technique provides better long-term pressure control.
Participants will be randomized into two groups and will:
Undergo either the standard NPDS procedure or the modified NPDS procedure using a 10/0 nylon mattress suture.
Visit the clinic for at least five scheduled follow-up appointments at 1 week, 1 month, 3 months, 6 months, and 9 months post-surgery.
Undergo comprehensive eye examinations at each visit, including Goldmann applanation tonometry for IOP, visual acuity testing, and monitoring for the development of cataracts or other surgical complications.
Study Overview
Status
Conditions
Detailed Description
The surgical protocol for Non-Penetrating Deep Sclerectomy (NPDS) begins with standardized aseptic preparation using 10% and 5% Betadine, followed by peribulbar anesthesia. In the standard Group 1 procedure, a 4 mm x 4 mm superficial scleral flap is created after conjunctival dissection, and Mitomycin-C (0.2 mg/mL) is applied for two minutes to inhibit scarring. The core of the surgery involves dissecting a deeper scleral flap to 90% thickness, unroofing Schlemm's canal to expose the trabeculo-descemet's membrane (TDM) and allow for aqueous percolation. The deep flap is then excised, the superficial flap is sutured with 10/0 nylon, and the conjunctiva is closed with watertight 7/0 Vicryl sutures.
For Group 2, the standard NPDS steps were followed until the excision of the deep scleral flap, at which point a specific mattress suture modification is introduced. Utilizing the Abdel Rahman and Habib technique, a 10/0 nylon suture is threaded through the sclera 2 mm lateral to the flap borders in an anteroposterior and postero-anterior fashion, creating a mattress configuration beneath the superficial flap to maintain the filtration space. Postoperatively, both groups follow a strict regimen of topical moxifloxacin and prednisolone acetate, which is tapered over six weeks, alongside a five-day course of oral ciprofloxacin to prevent infection and manage inflammation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Beni Suweif Governorate
-
Banī Suwayf, Beni Suweif Governorate, Egypt, 62511
- Beni-suef university Hospital
-
-
Giza Governorate
-
Giza, Giza Governorate, Egypt
- The Glaucoma Department at the Memorial Institute for Ophthalmic Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with primary or secondary open-angle glaucoma (OAG), either uncontrolled or intolerant to medical therapy
Exclusion Criteria:
- Past glaucoma procedures, including laser therapy, lens extraction, previous refractive surgery, angle closure, and neovascular glaucoma.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Group A (Conventional NPDS)
The standard procedure
|
The conjunctiva was made more visible by placing a 7/0 Vicryl corneal traction suture in the superior cornea.
Wescott scissors were used to excise a 10 mm fornix-based conjunctival flap, and minimum diathermy was used to achieve haemostasis.
Using a super blade, a 4 mm x 4 mm superficial scleral flap was made.
Then, a crescent knife was used for anterior dissection to a depth of around 50% of the scleral thickness, exposing the top 2 mm of the transparent cornea.
Under the scleral flap in the subconjunctival area, mitomycin-C (MMC®) sponges were positioned at a concentration of 0.2 mg/mL and moved towards the upper fornix.
They were kept in place for 2 minutes.
A balanced salt solution, volume 50 mL, was used for irrigation purposes.
The scleral spur was located by dissecting a deep scleral flap that began at the superficial flap's perimeter and continued to a depth equal to 90% of the thickness of the scleral bed.
To expose the trabecular meshwork (TDM), the roof of Schlemm's canal wa
|
|
Experimental: Group B (Modified NPDS)
Modified NPDS with Ahmed's sub-flap mattress suture
|
Up until the deep scleral flap was removed, this method was identical to the conventional NPDS.
Applying a mattress suture beneath the superficial scleral flap was the next step.
The superficial flap was sutured with a 10/0 nylon (Alcon®) that extended 1 mm beyond its outside edges.
The methodology originally described by Abdel Rahman and Habib was followed by the placement method.
The initial step in introducing the suture into the sclera was to line it with the left boundary of the superficial scleral flap and to do it in an anteroposterior manner.
This was done 2 mm outside the flap.
After that, it was moved horizontally under the flap again until it reached the right border.
Then, it was threaded postero-anteriorly, 2 mm laterally to the right flap edge.
Then, using McPherson forceps, the suture was fastened in a mattress configuration, with one limb placed near Schlemm's canal.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intraocular Pressure (IOP)
Time Frame: From baseline (1 day preoperative) to the five follow-up visits at one week, one month, three months, six months, and nine months.
|
IOP was measured using Goldmann applanation tonometry (GAT) at baseline (1 day preoperative) and during the planned follow-up visits.
|
From baseline (1 day preoperative) to the five follow-up visits at one week, one month, three months, six months, and nine months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Percentage of Patients with Postoperative IOP within 6-18 mmHg without Medication
Time Frame: At one week, one month, three months, six months, and nine months postoperatively.
|
If the intraocular pressure (IOP) stayed within the 6-18 mmHg range without medication throughout the follow-up period, the surgical result was deemed a full success.
Reaching the same intraocular pressure (IOP) range while using topical medicines was considered a qualified success.
Failure was defined as the inability to meet any of these requirements, which might lead to problems that could impair vision or need more severe glaucoma surgery.
|
At one week, one month, three months, six months, and nine months postoperatively.
|
|
Best Corrected Visual Acuity (BCVA)
Time Frame: From baseline 1 day preoperative and the five follow-up visits at one week, one month, three months, six months, and nine months.
|
Measured using Snellen's chart to assess baseline BCVA and any changes following the surgical procedure.
|
From baseline 1 day preoperative and the five follow-up visits at one week, one month, three months, six months, and nine months.
|
|
Postoperative Complications
Time Frame: At one week, one month, three months, six months, and nine months postoperatively.
|
Postoperative complications, such as iris prolapse, conjunctival leak, or IOP spikes, were assessed and compared between the two study groups.
|
At one week, one month, three months, six months, and nine months postoperatively.
|
|
Need for Reintervention
Time Frame: At one week, one month, three months, six months, and nine months postoperatively.
|
The need for intervention with bleb needling or YAG goniopuncture was assessed between the conventional and modified NPDS groups.
|
At one week, one month, three months, six months, and nine months postoperatively.
|
|
Postoperative Medication
Time Frame: At one week, one month, three months, six months, and nine months postoperatively.
|
The use of postoperative medications was evaluated and reported in the form of 'no drugs', 'one drug,' or 'two drugs' between the two study groups.
|
At one week, one month, three months, six months, and nine months postoperatively.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Amr Taha Orabi, Beni-Suef University
- Study Director: Mohamed Sayed Abouzeid, MD, Beni-Suef University
- Study Chair: Hazem Haroun, Beni-Suef University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FMBSUREC/06112022/Orabi
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Open Angle Glaucoma (OAG)
-
Medical University of BialystokRecruitingOpen Angle Glaucoma (OAG)Poland
-
Henry Ford Health SystemNot yet recruitingPrimary Open Angle Glaucoma (POAG) | Secondary Open Angle Glaucoma | Open Angle Glaucoma (OAG)United States
-
Avisi Technologies Inc.RecruitingOpen Angle Glaucoma (OAG)United States, South Africa
-
Iantrek, Inc.Enrolling by invitationOpen-angle Glaucoma (OAG)United States
-
Medical University of South CarolinaRecruitingOpen-angle Glaucoma (OAG) | Ocular Hypertension (OHT)United States
-
Glaukos CorporationRecruitingOcular Hypertension (OH) | Open Angle Glaucoma (OAG)United States
-
Barnet Dulaney Perkins Eye CentersAlcon, a Novartis CompanyRecruitingOpen Angle Glaucoma (OAG)United States
-
Qlaris Bio, Inc.RecruitingOAG - Open-Angle Glaucoma | OHT - Ocular HypertensionUnited States
-
Transcend Medical, Inc.CompletedOpen Angle Glaucoma (OAG)Germany
-
New World Medical, Inc.RecruitingOAG - Open-Angle GlaucomaCosta Rica, Chile, Honduras
Clinical Trials on Conventional Nonpenetrating Deep Sclerectomy (NPDS)
-
Helsinki University Central HospitalRecruitingNormal Tension GlaucomaFinland
-
University of ParmaCompleted
-
Germans Trias i Pujol HospitalPau Romera Romero; Jorge Loscos Arenas; Nevena Romanic Bubalo; Jordi Castellví...UnknownOpen Angle Glaucoma | Choroidal Thickness | Non Penetrating Deep SclerectomySpain
-
Germans Trias i Pujol HospitalRecruiting
-
Shahid Beheshti University of Medical SciencesActive, not recruitingGlaucoma | CataractIran, Islamic Republic of
-
Al-Azhar UniversityActive, not recruiting
-
King Saud UniversityUnknownCongenital GlaucomaSaudi Arabia
-
Institut Catala de RetinaHospital Universitario Ramon y Cajal; Hospital del Mar; Clinica Universidad de... and other collaboratorsCompletedOcular Hypertension | Open Angle GlaucomaSpain
-
Military Institute of Medicine, PolandCompletedGlaucoma, Open-Angle | Glaucoma, Primary Open Angle | Glaucoma Secondary
-
Military Institute of Medicine, PolandUnknownCataract | Open Angle GlaucomaPoland